Here, we found that patients who developed a PTM tended to have at baseline higher levels of immune senescent-like cells than no-PTM patients; in particular, within the cohort of patients transplanted for HCC, the numbers of circulating senescent-like CD4+ and CD8+ T cells were significantly higher, thus suggesting that immune senescence at baseline may be an additional predictive marker in patients transplanted for HCC. This evidence concerns the gene CD8A and hepatocellular carcinoma.